2023-510389-28-00招募中3 期
An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- VectivBio AG
- 入组人数
- 101
- 试验地点
- 36
- 主要终点
- 1. Adverse events (AEs; system organ class, frequency and severity)
研究概览
简要总结
To assess long-term safety and tolerability of apraglutide in subjects with SBS-IF
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Males and females with a diagnosis of SBS-IF secondary to surgical resection of the small intestine, with CIC or stoma, who were trial subjects of TA799-007 or TA799-013 (parent trials) and: a. Did not meet any stopping criteria b. For those subjects who completed a parent trial, they have received a minimum of 70% of the planned doses in the trial (unless an AE precluded the subject from meeting this percentage; in this case, the Investigator will decide if the subject will benefit from enrolling in the trial) c. For those subjects who completed a parent trial, they have completed the last two scheduled visits of the parent trial. Subjects who were forced to withdraw from TA799-007 or TA799-013 for logistical reasons not related to the efficacy or safety of apraglutide (e.g., hospitalization for a car accident, coronavirus disease [COVID-19] pandemic, emergency surgery, etc.), which resulted in several consecutive missed doses, including the last 2 visits, may be eligible to participate in this trial upon approval by the Medical Monitor d. When the required number of trial-completed subjects is achieved in a parent trial, the remaining subjects still on treatment may prematurely discontinue the parent trial and roll over into TA799-012 (before completing all the parent trial visits). Criterion “d” was not applicable to sites in France
- •Able to give informed consent and agree to follow the details of participation as outlined in this protocol
- •Women of childbearing potential must agree to use a highly effective method of contraception during the trial and for 4 weeks after the EOT/early termination visit. Such methods include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner. To be considered sterilized or infertile, females must have undergone surgical sterilization (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be postmenopausal (defined as at least 12 months amenorrhea without an alternative medical cause, may be confirmed with follicle-stimulating hormone [FSH] test in case of doubt). Women who do not engage in heterosexual intercourse will be allowed to join the trial without contraception following a thorough discussion with the Investigator to determine if this is feasible for the subject. The following methods are not considered acceptable methods of contraception: calendar, ovulation, symptothermal, post-ovulation methods, withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method
- •Male subjects with a female partner of childbearing potential must commit to practice methods of contraception and abstain from sperm donation during the trial and for 2 weeks after the EOT/early termination visit. Nevertheless, if their partners are women of childbearing potential, they must agree to practice contraception and use a highly effective method of contraception during the trial and for 4 weeks after the EOT/early termination visit. Such methods include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device; intrauterine hormone-releasing system, bilateral tubal occlusion
排除标准
- •Subject not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements
- •Subject not undergoing a baseline colonoscopy (if anatomically feasible) or CT/MRI colonography and not having had all identified colonic or rectal polyps removed
- •Judged not eligible by the Investigator for any other reason
结局指标
主要结局
1. Adverse events (AEs; system organ class, frequency and severity)
1. Adverse events (AEs; system organ class, frequency and severity)
2. Occurrence of clinically relevant AEs of special interest (AESIs): o Injection site reactions o Gastrointestinal (GI) obstructions o Gallbladder, biliary and pancreatic disease o Fluid overload o Colorectal polyps o Malignancies
2. Occurrence of clinically relevant AEs of special interest (AESIs): o Injection site reactions o Gastrointestinal (GI) obstructions o Gallbladder, biliary and pancreatic disease o Fluid overload o Colorectal polyps o Malignancies
3. Clinical chemistry, hematology, hemostasis and urinalysis
3. Clinical chemistry, hematology, hemostasis and urinalysis
4. Occurrence of clinically relevant changes in vital signs (systolic and diastolic blood pressure, heart rate)
4. Occurrence of clinically relevant changes in vital signs (systolic and diastolic blood pressure, heart rate)
5. Occurrence of clinically relevant changes in electrocardiogram (ECG; intervals and rhythm)
5. Occurrence of clinically relevant changes in electrocardiogram (ECG; intervals and rhythm)
次要结局
- 1. Change from baseline in PS volume at Weeks 52, 104, 152, 216, 264 and 312
- 2. Change from baseline in PS frequency at Weeks 52, 104, 152, 216, 264 and 312
- 3. Change from baseline in PS composition at Weeks 52, 104, 152, 216, 264 and 312
- 4. Change from baseline in PS infusion time at Weeks 52, 104, 152, 216, 264 and 312
- 5. Percentage of subjects reaching enteral autonomy by Weeks 52, 104, 152, 216, 264 and 312
- 6. Change from baseline in body weight at Weeks 52, 104, 152, 216, 264 and 312
- 7. Change from baseline on the Pittsburgh Sleep Quality Index (PSQI) at Weeks 52, 104, 152, 216, 264 and 312
- 8. Change from baseline on the Patient Global Impression of Change (PGIC) at Weeks 52, 104, 152, 216, 264 and 312
- 9. Change from baseline on the Patient Global Impression of Severity (PGIS) at Weeks 52, 104, 152, 216, 264 and 312
- 10. Changes from baseline on Patient Global Impression of Treatment Satisfaction (PGI-TS) at Weeks 52, 104, 152, 216, 264 and 312
- 11. Changes from baseline on Patient Global Impression of Satisfaction with Parenteral Support (PGI-SPS) at Weeks 52, 104, 152, 216, 264 and 312
- 12. Changes from baseline on Patient Global Impression of Parenteral Support Impact (PGI-PSI) at Weeks 52, 104, 152, 216, 264 and 312
- 13. Change from baseline on the Short Form (36) Health Survey (SF-36) at Weeks 52, 104, 152, 216, 264 and 312
- 14. Change from baseline on the EuroQoL-5 dimension - 5 level survey (EQ-5D-5L) at Weeks 52, 104, 152, 216, 264 and 312
研究者
Clinical Trial Information Desk
Scientific
VectivBio AG
研究点 (36)
Loading locations...
相似试验
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersshort bowel syndromeEUCTR2020-005513-41-DEVectivBio AG154
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeshort bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-005513-41-FRVectivBio AG154
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeshort bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-005513-41-DKVectivBio AG154
招募中
3 期
Apraglutide Open-Label Phase 3 Extension Trialshort bowel syndrome and intestinal failure (SBS-IF)JPRN-jRCT2031220255Akinori Kashiyama12
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeshort bowel syndromeEUCTR2020-005513-41-HUVectivBio AG154